Skip to content
Back to explorer
Printable monograph

Pyrimidine analog

5-Fluorouracil

Adrucil · 5-FU

Pyrimidine analog · approved 1962 · 9 citations · FAERS AKI reporting ROR 1.96 (95% CI 1.86–2.06, 1,607 AKI reports)

Recent· through 2024
Deeply sourced8/9 · 7 signals
  • Met: 9 citations
  • Not met: 12+ references
  • Met: Accrued over 10+ years (span: 37y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2024
  • Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A GI-cancer mainstay that is mostly kidney-safe until it teams up with mitomycin.

MildFluoropyrimidine antimetabolite
Colorectal cancerGastric and pancreatic cancerBreast cancerHead and neck cancer

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Very short half-life with enzymatic (DPD) catabolism, so IV 5-FU is not removed or managed by dialysis and needs no CrCl-based adjustment; the renally cleared catabolite is not the toxic species.PMID 11219485 (opens PubMed in a new tab)
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: FAVLYXA, Oct 2026. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Intrinsic nephrotoxicity is low; the recognized vascular renal complication is thrombotic microangiopathy/hemolytic-uremic syndrome, classically with mitomycin C, with 5-FU as a frequent co-agent. In TTP/HUS series the most common antecedent chemotherapy is mitomycin C plus 5-FU.Source: Martinez Frances et al., Med Clin (Barc) 1997

Onset & rechallenge

Time to injuryDelayed (>6 weeks / cumulative)

TMA typically delayed (weeks to months); prerenal effects can be acute with GI toxicity.

Distilled from: “TMA often delayed (weeks to months); prerenal effects acute with GI toxicity.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Thrombotic Microangiopathy#1 · Signaturequalitative — no citable incidence

    Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

  2. Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Also documented as kidney-sparing

5-Fluorouracil — Generally renally well tolerated as a single agent. Rare TMA when combined with mitomycin; mucositis, cardiotoxicity.

The spared
Appears in 1 documented synergy combination

Mechanism of kidney injury

5-FU itself is largely renally well tolerated; in combination (especially with mitomycin C) it contributes to chemotherapy-associated thrombotic microangiopathy via endothelial injury, with glomerular capillary fibrin thrombi, microangiopathic hemolysis and progressive renal failure that may appear months into therapy. Severe diarrhea/mucositis can cause prerenal AKI. Preclinically, 5-FU can induce direct renal oxidative/apoptotic tubular injury (p53/Bax/caspase-3, KIM-1), though this is not the dominant clinical lesion. DPD deficiency markedly amplifies systemic (not specifically renal) toxicity.

Clinical presentation

In TMA/HUS: microangiopathic hemolytic anemia (schistocytes, elevated LDH), thrombocytopenia and progressive renal failure, sometimes months after starting therapy and often dose-cumulative with mitomycin; otherwise prerenal azotemia from GI losses.

Management

Discontinue offending agents for TMA/HUS and provide supportive care (the syndrome carries high mortality; plasma exchange has limited efficacy, and complement-directed therapy is used in select cases); rehydrate for prerenal AKI. Renal recovery is variable and may be incomplete in established TMA.Lesion-level management framework

Risk factors

  • Concurrent mitomycin C (dominant TMA driver)
  • Cumulative mitomycin/fluoropyrimidine exposure
  • Volume depletion from diarrhea/mucositis
  • DPD (DPYD) deficiency for severe systemic toxicity

Prevention

  • Recognize mitomycin as the dominant TMA driver and cap its cumulative dose
  • Hydration and prompt management of GI toxicity
  • Consider DPYD genotyping before fluoropyrimidine start
Anticancer mechanism· how it treats cancer

Fluoropyrimidine antimetabolite whose active metabolites (FdUMP, FUTP, FdUTP) inhibit thymidylate synthase and incorporate into RNA and DNA, blocking nucleotide synthesis. Catabolized predominantly by dihydropyrimidine dehydrogenase (DPD). Backbone of colorectal, gastric, pancreatic, breast and head and neck regimens.

§04

Clinical depth

Renal dose adjustment

No standard CrCl-based dose adjustment for IV 5-FU (catabolism is enzymatic via DPD, not renal); dose by toxicity and consider DPYD-genotype-guided reduction. In significant renal impairment, monitor closely but renal clearance is a minor pathway.

Dialyzability & ESKD dosing

5-FU has a very short half-life and is enzymatically catabolized; it is not managed by dialysis. Its catabolite fluoro-beta-alanine is renally excreted and can accumulate in renal failure but is not the toxic species.

Differential diagnosis

Chemo-associated TMA/HUS (Coombs-negative microangiopathic hemolysis, schistocytes, thrombocytopenia, normal-ish coagulation, often mitomycin-related) vs prerenal azotemia from diarrhea (volume-responsive, low FeNa) vs other causes of AKI. ADAMTS13 is usually not severely deficient, separating it from classic TTP.

Monitoring

  • CBC, LDH, haptoglobin and creatinine - rising LDH with thrombocytopenia signals TMA
  • Volume/diarrhea status each cycle
  • DPYD genotype or phenotype where available before fluoropyrimidine start

Key trials & series

  • Mitomycin-5-FU HUS literature (Jain Pathology 1987; Martinez Frances Med Clin 1997 35-patient TTP/HUS series)
  • Henricks Lancet Oncol 2018 - prospective DPYD genotype-guided fluoropyrimidine dosing safety study

Clinical pearls

  • Single-agent 5-FU is renally benign - when TMA appears, look hard at the mitomycin C in the regimen and its cumulative dose.
  • Fluoropyrimidine toxicity is enzymatic (DPD), not renal - DPYD genotyping, not CrCl, is the key safety screen.
  • Mitomycin/5-FU TMA can surface months in and is cumulative-dose related; persistent thrombocytopenia plus hemolysis should not be dismissed.
Where it strikes· nephron segments & injury signatures

Nephron segments

Vasculature / Endothelium

Glomerular & peritubular capillaries

Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the Pyrimidine analog class.

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

  • Mucositis and diarrhea

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

  • Transaminitis (methotrexate)

Hematologic

Cytopenias, thrombosis, TMA

  • Myelosuppression

Pulmonary

Pneumonitis, ILD, effusions, hypertension

  • Methotrexate / gemcitabine pneumonitis
§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 1987–2018 · 1 since 2016
101987: 1 citation1999: 1 citation2001: 1 citation2002: 1 citation2004: 1 citation2014: 1 citation2018: 1 citation19871990200020102018

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkA review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.Fung MC et al. · Cancer · 1999 · PMID 10223245Antimetabolite-associated HUS review noting mitomycin-C/5-FU as confounding co-exposures.
  2. 2.Mitomycin C associated hemolytic uremic syndrome.Jain S et al. · Pathology · 1987 · PMID 3108839Chemotherapy-associated HUS/TMA (mitomycin with 5-FU) with characteristic renal histology.
  3. 3.High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.Hofheinz RD et al. · Onkologie · 2002 · PMID 12119460Prospective series documenting HUS cases with 5-FU plus mitomycin C.
  4. 4.[Mitomycin-induced hemolytic uremia syndrome].Steffens F · Dtsch Med Wochenschr · 2004 · PMID 15227598Mitomycin/5-FU-associated hemolytic uremic syndrome case context.
  5. 5.Mitigation of 5-Fluorouracil induced renal toxicity by chrysin via targeting oxidative stress and apoptosis in wistar rats.Rashid S et al. · Food Chem Toxicol · 2014 · PMID 24486618Preclinical evidence of direct 5-FU renal oxidative/apoptotic tubular injury.
  6. 6.DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.Henricks LM et al. · Lancet Oncol · 2018 · PMID 30348537DPD-deficiency toxicity context; genotype-guided dosing improves fluoropyrimidine safety.
  7. 7.Anticancer drug-induced kidney disorders.Kintzel PE · Drug Saf · 2001 · PMID 11219485Onconephrology review of antimetabolite and TMA/HUS mechanisms.
FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY Increased risk of serious adverse reactions or death in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating FAVLYXA unless immediate treatment is necessary. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency [see Warnings and Precautions (5.1) ]. WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY Increased risk of serious adverse reactions or death in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating FAVLYXA unless immediate treatment is necessary. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency. ( 5.1 )

Kidney rows of the label's dosage tables

From the FAVLYXA label (Oct 2026) · DailyMed

No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 78,755 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 7 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Thrombotic Microangiopathycorroborated · ROR 3.57
  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Glomerular Injury / Proteinuria
ROR 5.4895% CI 5.06–5.93· 630 reports· IC025 2.30
Thrombotic Microangiopathy
ROR 3.5795% CI 3.13–4.07· 231 reports· IC025 1.62
Electrolyte Disturbance
ROR 3.4995% CI 3.36–3.63· 2,674 reports· IC025 1.70
SIADH / Hyponatremia
ROR 2.4995% CI 2.32–2.67· 816 reports· IC025 1.19
Acute Tubular Necrosis
ROR 2.1095% CI 1.70–2.60· 87 reports· IC025 0.74
Fanconi Syndrome
ROR 1.5495% CI 1.09–2.19· 32 reports· IC025 0.07
Hypertension
ROR 1.1695% CI 1.11–1.22· 1,751 reports· IC025 0.14
FAERS outcomes & reporting trend· 14% of reports w/ death · 40.1% w/ hospitalization
14%

Reported with a death outcome

11,053 of 78,755 reports

40.1%

Reported with hospitalization

31,559 of 78,755 reports

Reports per year

  • 2015: 2,414 reports
  • 2016: 2,822 reports
  • 2017: 3,257 reports
  • 2018: 4,970 reports
  • 2019: 5,215 reports
  • 2020: 4,353 reports
  • 2021: 4,349 reports
  • 2022: 5,809 reports
  • 2023: 6,381 reports
  • 2024: 6,049 reports
  • 2025: 6,761 reports
  • 2026: 5,122 reports

Reports received per year, 2015–2026 · most recent year is partial · 21,253 of the 78,755 reports predate 2015 and are not drawn.

FAERS adverse-event signal — all organ systems· 8 systems · 78,755 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 1.9695% CI 1.86–2.06· 1,607 AKI reports· IC025 0.88·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.
Gastrointestinal
Diarrhoea7,146Nausea5,128Vomiting4,075Abdominal Pain1,933Mucosal Inflammation1,846
Blood & lymphatic
Neutropenia5,297Thrombocytopenia3,048Febrile Neutropenia2,928Anaemia2,622Leukopenia1,646
General / constitutional
Fatigue3,393Pyrexia3,121Asthenia2,618
Metabolic & electrolyte
Decreased Appetite2,110Dehydration1,742
Nervous system
Neuropathy Peripheral3,555
Respiratory
Dyspnoea2,090Pulmonary Embolism1,419
Skin
Rash1,612
Immune / infection
Sepsis1,411
Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where 5-Fluorouracil sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Capecitabine

Xeloda · Pyrimidine analog (oral 5-FU)

Profile

Diarrhea-driven prerenal AKI; dose-adjust for CrCl.

PRETMA
Mild#1 · 100% phenotype match

Docetaxel

Taxotere · Taxane

Profile

Fluid retention; low direct renal toxicity.

PRECYSTTMA
Mild#2 · 73% phenotype match

Ruxolitinib

Jakafi · JAK1/2 inhibitor

Profile

Tumor lysis in myelofibrosis; renally adjusted.

PRELYTETMA
Mild#3 · 71% phenotype match

Trifluridine/tipiracil

Lonsurf · Oral fluoropyrimidine + TP inhibitor

Profile

Tipiracil is renally cleared; reduced GFR raises exposure and early severe neutropenia; dose-reduce in renal impairment.

PRE
Moderate#4 · 68% phenotype match

Ponatinib

Iclusig · BCR-ABL TKI

Profile

Vascular toxicity and hypertension.

HTNPRETMA
Moderate#5 · 68% phenotype match

Doxifluridine

Furtulon · Antimetabolite (oral 5-FU prodrug)

Profile

5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.

TMALYTEPRE
Moderate#6 · 67% phenotype match
Compare 5-Fluorouracil with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Antimetabolites

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1CapecitabineMild
  2. 2CladribineMild
  3. 35-Fluorouracil· this agentFAERS AKIMild
  4. 4HydroxyureaFAERS AKIMild
  5. 4NelarabineFAERS AKIMild
  6. 6DecitabineFAERS AKIMild
  7. 7Trifluridine/tipiracilModerate
  8. 8PralatrexateModerate
  9. 9Carmofur (HCFU)FAERS n/aModerate
  10. 9DoxifluridineModerate
  11. 11Methotrexate (high-dose)FAERS AKIModerate
  12. 11RaltitrexedFAERS AKIModerate
  13. 13FludarabineFAERS AKIModerate
  14. 13PentostatinFAERS AKIModerate
  15. 15AzacitidineFAERS AKIModerate
  16. 15ClofarabineFAERS AKIModerate
  17. 15CytarabineFAERS AKIModerate
  18. 15PemetrexedFAERS AKIModerate
  19. 19Tegafur-uracil (UFT)Severe
  20. 20GemcitabineFAERS AKISevere

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to 5-Fluorouracil’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on 5-Fluorouracil; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

  1. Fuchs, Charles S — their work on 5-Fluorouracil, on PubMed (opens in a new tab)2 papers · 270 citesPMID 30718072 (opens PubMed in a new tab)PMID 14523796 (opens PubMed in a new tab)
  2. Fujita, Ken-ichi — their work on 5-Fluorouracil, on PubMed (opens in a new tab)2 papers · 256 citesPMID 26604633 (opens PubMed in a new tab)PMID 22722580 (opens PubMed in a new tab)
  3. Boulikas, Teni — their work on 5-Fluorouracil, on PubMed (opens in a new tab)2 papers · 221 citesPMID 20138443 (opens PubMed in a new tab)PMID 19604121 (opens PubMed in a new tab)
  4. Chudek, Jerzy — their work on 5-Fluorouracil, on PubMed (opens in a new tab)2 papers · 22 citesPMID 38256147 (opens PubMed in a new tab)PMID 35979324 (opens PubMed in a new tab)
  5. Hurwitz, Herbert — their work on 5-Fluorouracil, on PubMed (opens in a new tab)2 papers · 185 citesPMID 17145522 (opens PubMed in a new tab)PMID 16301832 (opens PubMed in a new tab)

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 131 clinical records among the 300 most-relevant of 364 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.